

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 May 2006 (11.05.2006)

PCT

(10) International Publication Number
WO 2006/048889 AI

(51) International Patent Classification⁷: C07D 498/06

(21) International Application Number:
PCT/IN2004/000343

(22) International Filing Date:
8 November 2004 (08.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): NEULAND LABORATORIES LTD. [IN/IN]; Flat No. 204, IInd Floor, Meridian Plaza, 6-3-853/1, Ameerpet, Hyderabad 500 016, Andhra Pradesh (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RAMMOHAN RAO, Davuluri [IN/IN]; Neuland Laboratories Ltd., Flat No. 204, IInd Floor, Meridian Plaza, 6-3-853/1, Ameerpet, Hyderabad 500 016, Andhra Pradesh (IN). DWIVEDI, Shriprakash, Dhar [IN/IN]; Neuland Laboratories Ltd., Flat No. 204, IInd Floor, Meridian Plaza, 6-3-853/1, Ameerpet, Hyderabad 500 016, Andhra Pradesh (IN). SREENIVASULU, Pamujula [IN/IN]; Neuland Laboratories Ltd., Flat No. 204, IInd Floor, Meridian Plaza, 6-3-853/1, Ameerpet, Hyderabad 500 016, Andhra Pradesh (IN). SAHU, Arabinda [IN/IN]; Neuland Laboratories Ltd., Flat No. 204, IInd Floor, Meridian Plaza, 6-3-853/1, Ameerpet, Hyderabad 500 016, Andhra Pradesh (IN). TRINADHACHARI, Ganala, Naga [IN/IN]; Neuland Laboratories Ltd., Flat No. 204, IInd Floor, Meridian Plaza, 6-3-853/1, Ameerpet, Hyderabad 500 016, Andhra Pradesh (IN). SASI KIRAN, Surapaneni [IN/IN]; Neuland Laboratories Ltd., Flat No. 204, IInd Floor, Meridian Plaza, 6-3-853/1, Ameerpet, Hyderabad 500 016, Andhra Pradesh (IN).

(74) Common Representative: RAMMOHAN RAO, Davuluri; Neuland Laboratories Ltd., Flat No. 204, IInd Floor, Meridian Plaza, 6-3-853/1, Ameerpet, Hyderabad 500 016, Andhra Pradesh (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17 (iv))

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: AN IMPROVED PROCESS FOR THE PREPARATION OF LEVOFLOXACIN HEMIHYDRATE

(57) Abstract: The present invention relates to an improved process for preparation of Levofloxacin hemihydrate having single individual impurity not more than 0.1% and free from particulate matter and from the other enantiomer (R-form) which comprises dissolving levofloxacin technical grade in aqueous alkaline solution, treating the resulting solution with activated carbon at room temperature, removing the undissolved particulate matter filtration, bringing the pH of the aqueous alkaline levofloxacin solution to neutral using dilute mineral acid, removing the precipitated particulate matter by filtration, acidifying the resulting solution, treating the acidified solution with activated carbon at room temperature, filtering the undissolved particulate matter by filtration, neutralizing the acidic solution, filtering again to remove any particulate matter present and, extracting the resulting product with chlorinated solvent and concentrating under vacuum using aqueous tetrahydrofuran or in admixture with other organic solvents to get highly pure levofloxacin hemihydrate having single individual impurity is less than 0.1% and free from particulate matter and from the other enantiomer (R-form).

WO 2006/048889 A1